Metabolites (Apr 2024)

Computational Applications: Beauvericin from a Mycotoxin into a Humanized Drug

  • Charbel Al Khoury,
  • Sima Tokajian,
  • Nabil Nemer,
  • Georges Nemer,
  • Kelven Rahy,
  • Sergio Thoumi,
  • Lynn Al Samra,
  • Aia Sinno

DOI
https://doi.org/10.3390/metabo14040232
Journal volume & issue
Vol. 14, no. 4
p. 232

Abstract

Read online

Drug discovery was initially attributed to coincidence or experimental research. Historically, the traditional approaches were complex, lengthy, and expensive, entailing costly random screening of synthesized compounds or natural products coupled with in vivo validation largely depending on the availability of appropriate animal models. Currently, in silico modeling has become a vital tool for drug discovery and repurposing. Molecular docking and dynamic simulations are being used to find the best match between a ligand and a molecule, an approach that could help predict the biomolecular interactions between the drug and the target host. Beauvericin (BEA) is an emerging mycotoxin produced by the entomopathogenic fungus Beauveria bassiana, being originally studied for its potential use as a pesticide. BEA is now considered a molecule of interest for its possible use in diverse biotechnological applications in the pharmaceutical industry and medicine. In this manuscript, we provide an overview of the repurposing of BEA as a potential therapeutic agent for multiple diseases. Furthermore, considerable emphasis is given to the fundamental role of in silico techniques to (i) further investigate the activity spectrum of BEA, a secondary metabolite, and (ii) elucidate its mode of action.

Keywords